Spotted in the wilds of Puget Sound last weekend: Chief Scientific Officer Diane Hollenbaugh repping the vast oncology research community and the collective good it is doing! As #NationalCancerResearchMonth comes to a close, Bonum Therapeutics wants to acknowledge the tireless efforts and enduring optimism of those working to create a better future for patients with cancer. #NCRM2024 #PNW #ScienceSelfie
hi Diane
Early/Late Phase and Regulatory Strategy, RWE & RWD, Market Access, Logistics at Parexel Biotech
"The key to advancing precision oncology is to democratize the data." Stacy Hurt, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/ex_7vjQz #ParexelBiotech #PatientData #Oncology #NovelInsights
For those who missed Race Oncology’s Sharewise webinar yesterday, you can access a copy via the link below. During the webinar, CEO Dr Daniel Tillett provides a detailed update on Race's latest progress, upcoming milestones and why Race makes an exciting proposition for investors. He also answers a range of questions from investors, including what he looks for when investing in #biotechs. He explains, “You’re looking for undervalued assets that are going to appreciate over time." https://lnkd.in/gvHyFdtq
Watch our webinar with Race Oncology featuring CEO Daniel Tillett. The webinar features a presentation, followed by a live Q&A. Key topics: - Background to Race Oncology and their developments - What bisantrene could mean for cancer patients around the world - Why cardioprotection is so important in regards to cancer treatment - What stage they are at with the clinical development process - The company's upcoming milestones - Why investors should be interested in Race Oncology Watch here: https://hubs.la/Q02zC8n80 Thank you Daniel for your time today.
"The key to advancing precision oncology is to democratize the data." Stacy Hurt, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/ed_c9k_M #ParexelBiotech #PatientData #Oncology #NovelInsights
"The key to advancing precision oncology is to democratize the data." Stacy Hurt, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/ed_c9k_M #ParexelBiotech #PatientData #Oncology #NovelInsights
Embrace the latest insights in #IQVIAInstitute Global #Oncology Trends report, where we offer a comprehensive outlook on the oncology landscape through 2027! From pioneering treatments to emerging areas of research, the report delves into key mechanisms, cancer types, and #clinicaltrial diversity. Join in the discussion on patient access, innovative therapies, and the impact on healthcare budgets. Read the full report now and be a part of the transformative journey in oncology: https://bit.ly/3EhwK1k
Personalized Cancer Treatments: Top Investment Insights Investing in personalized cancer treatments offers promising returns and transformative potential. Our latest blog provides key insights into this innovative market, highlighting opportunities and trends. Discover where to invest in the future of oncology! #CancerTreatment #InvestmentInsights #PersonalizedMedicine
HER2 negative Breast Cancer Pipeline and Companies (Updated): Clinical Trials, Therapies, Route of Administration, Mechanism of Action and Developments by DelveInsight #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Check-out our new whitepaper, The Challenge of Financial Toxicity in Cancer Care: a Focus on Oral Oncology, to learn how our care model is uniquely positioned to alleviate out-of-pocket costs for cancer patients, reducing barriers to medication access and improving adherence and clinical outcomes. Read the entire whitepaper here - https://lnkd.in/eafYU3dF #TeamShields #FinancialToxicity #ElevatingSpecialtyPharmacy
Precision oncology has transformed cancer treatment, offering personalized therapies based on genetic and molecular profiles. However, as the field advances, so do the complexities. Join us for an expert panel discussion covering the challenges and opportunities of clinical equipoise in precision oncology trials. 🔍 Topics to be explored: - Clinical Equipoise in Precision Oncology Trials - Hybrid Trial Designs - Regulatory Insights - Patient-Centric Approaches Register now to secure your spot for this webinar! #Oncology #PrecisionOncology #TrialDesign #PatientsFirst
Appreciate this interview with oncology leaders on Drug Shortages in the US - Kirollos Hanna, PharmD, BCPS, BCOP, FACCC American Cancer Society #AmericanCancerSociety #Cancer #DrugShortage #Healthcare #OncoDaily #Oncology #OncologyLeaders
Senior Writer/Consultant
1moFantastic work and inspiring message!